Comparison of pirfenidone and corticosteroid treatments at the COVID‐19 pneumonia with the guide of artificial intelligence supported thoracic computed tomography. Issue 12 (17th October 2021)

• Record Type: Journal Article
• Authors: Acat, Murat; Yildiz Gulhan, Pinar; Oner, Serkan; Turan, Muhammed Kamil
• Is Part Of: International journal of clinical practice. Volume 75:Issue 12(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-10-17
• Subjects: Clinical medicine -- Periodicals; Medicine -- Periodicals; 610.5
• DOI: 10.1111/ijcp.14961
• Languages: English
• ISSNs: 1368-5031

Abstract

Abstract: Aim: We aimed to investigate the effect of short‐term pirfenidone treatment on prolonged COVID‐19 pneumonia. Method: Hospital files of patients hospitalised with a diagnosis of critical COVID‐19 pneumonia from November 2020 to March 2021 were retrospectively reviewed. Chest computed tomography images taken both before treatment and 2 months after treatment, demographic characteristics and laboratory parameters of patients receiving pirfenidone + methylprednisolone (n = 13) and only methylprednisolones (n = 9) were recorded. Pulmonary function tests were performed after the second month of the treatment. CT involvement rates were determined by machine learning. Results: A total of 22 patients, 13 of whom (59.1%) were using methylprednisolone + pirfenidone and 9 of whom (40.9%) were using only methylprednisolone were included. When the blood gas parameters and pulmonary function tests of the patients were compared at the end of the second month, it was found that the FEV1, FEV1%, FVC and FVC% values were statistically significantly higher in the methylprednisolone + pirfenidone group compared with the methylprednisolone group ( P = .025, P = .012, P = .026 and P = .017, respectively). When the rates of change in CT scans at diagnosis and second month of treatment were examined, it was found that the involvement rates in the methylprednisolone + pirfenidone group were statistically significantly decreased ( P < .001). Conclusion: Antifibrotic agents can reduce fibrosis that may develop in the future. These can also help dose reduction and/or non‐use strategy for methylprednisolone therapy, which has many side effects. Further large series and randomised controlled studies are needed on this subject.